Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 25, 2012, Pages 9959-9964

  Ostrov, David A ^a   Grant, Barry J ^b   Pompeu, Yuri A ^c   Sidney, John ^d   Harndahl, Mikkel ^e   Southwood, Scott ^d   Oseroff, Carla ^d   Lu, Shun ^a   Jakoncic, Jean ^f   De Oliveira, Cesar Augusto F ^g   Yang, Lun ^h   Mei, Hu ^h   Shi, Leming ^h   Shabanowitz, Jeffrey ⁱ   English, A Michelle ⁱ   Wriston, Amanda ⁱ   Lucas, Andrew ^j   Phillips, Elizabeth ^j   Mallal, Simon ^j   Grey, Howard M ^d   Sette, Alessandro ^d   Hunt, Donald F ⁱ   Buus, Soren ^e   Peters, Bjoern ^d   more..

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c University of Florida ^*  (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f BROOKHAVEN NATIONAL LABORATORY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

ⁱ UNIVERSITY OF VIRGINIA   (United States)

^j MURDOCH UNIVERSITY   (Australia)

more..

Author keywords

3D structure; Binding site; Small molecule

Indexed keywords

ABACAVIR; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ARTICLE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN STRUCTURE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; DRUG HYPERSENSITIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, MOLECULAR; PEPTIDES;

EID: 84862532297     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1207934109     Document Type: Article

References (42)

1. Rauch A, et al. (2006) Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 43:99-102.
2. + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28:822-832.
3. Uetrecht J (2007) Idiosyncratic drug reactions: Current understanding. Annu Rev Pharmacol Toxicol 47:513-539.
4. Phillips EJ, Mallal SA (2009) HLA and drug-induced toxicity. Curr Opin Mol Ther 11:231-242.
5. Lavergne SN, Park BK, Naisbitt DJ (2008) The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol 8:299-307.
6. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M (2001) Metabolic activation in drug allergies. Toxicology 158:11-23.
7. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK (2002) The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicology 181-182:55-63.
8. Pichler WJ, et al. (2006) Pharmacological interaction of drugs with immune receptors: The p-i concept. Allergol Int 55:17-25.
9. Sidney J, Peters B, Frahm N, Brander C, Sette A (2008) HLA class I supertypes: A revised and updated classification. BMC Immunol 9:1.
10. Bharadwaj M, et al. (2011) Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 52:501-531.
11. Yang CW, et al. (2007) HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 120:870-877.
12. Yang L, Chen J, He L (2009) Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLOS Comput Biol 5:e1000441.
13. Sidney J, et al. (2008) Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 4:2.
14. Harndahl M, et al. (2009) Peptide binding to HLA class I molecules: Homogenous, high-throughput screening, and affinity assays. J Biomol Screen 14:173-180.
15. Harndahl M, Rasmussen M, Roder G, Buus S (2011) Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods 374:5-12.
16. Brenke R, et al. (2009) Fragment-based identification of druggable "hot spots" of proteins using Fourier domain correlation techniques. Bioinformatics 25:621-627.
17. Friesner RA, et al. (2004) Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749.
18. Case DA, et al. (2005) The Amber biomolecular simulation programs. J Computat Chem 26:1668-1688.
19. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW (2008) Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 26:171-203.
20. Rudolph MG, Wilson IA (2002) The specificity of TCR/pMHC interaction. Curr Opin Immunol 14:52-65.
21. Shimizu Y, DeMars R (1989) Production of human cells expressing individual transferred HLA-A, -B, -C genes using an HLA-A, -B, -C null human cell line. J Immunol 142:3320-3328.
22. Udeshi ND, Compton PD, Shabanowitz J, Hunt DF, Rose KL (2008) Methods for analyzing peptides and proteins on a chromatographic timescale by electron-transfer dissociation mass spectrometry. Nat Protoc 3:1709-1717.
23. Zarling AL, et al. (2006) Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci USA 103:14889-14894.
24. Shastri N, Schwab S, Serwold T (2002) Producing nature's gene-chips: The generation of peptides for display by MHC class I molecules. Annu Rev Immunol 20:463-493.
25. Tenzer S, et al. (2005) Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 62:1025-1037.
26. Starr TK, Jameson SC, Hogquist KA (2003) Positive and negative selection of T cells. Annu Rev Immunol 21:139-176.
27. Faletto MB, et al. (1997) Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 41:1099-1107.
28. Melroy J, Nair V (2005) The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Curr Pharm Des 11:3847-3852.
29. Martin AM, et al. (2007) Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 21:1233-1244.
30. Day PM, Yewdell JW, Porgador A, Germain RN, Bennink JR (1997) Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc Natl Acad Sci USA 94:8064-8069.
31. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN (1996) Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565-571.
32. Yewdell JW, Haeryfar SM (2005) Understanding presentation of viral antigens to CD8+ T cells in vivo: The key to rational vaccine design. Annu Rev Immunol 23:651-682.
33. Amir AL, et al. (2010) Allo-HLA reactivity of virus-specific memory T cells is common. Blood 115:3146-3157.
34. Ko TM, et al. (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 128:1266-1276.
35. Dai S, et al. (2010) Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc Natl Acad Sci USA 107:7425-7430.
36. Hung SI, et al. (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102:4134-4139.
37. Chung WH, et al. (2004) Medical genetics: A marker for Stevens-Johnson syndrome. Nature 428:486.
38. Mallal S, et al.; PREDICT-1 Study Team (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568-579.
39. Sidney J, et al. (2001) Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol, Unit 18.3.
40. Smith KJ, et al. (1996) An altered position of the α2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 4:203-213.
41. Kjer-Nielsen L, et al. (2003) A structural basis for the selection of dominant αβ T cell receptors in antiviral immunity. Immunity 18:53-64.
42. Gras S, et al. (2010) Allelic polymorphism in the T cell receptor and its impact on immune responses. J Exp Med 207:1555-1567.